Posted on October 7th, 2019

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at the disease areas within psychiatry and neurology. (Lundbeck website; 2019; )

Our partnership concerns the research on multiple small molecule drug discovery projects aiming to integrate high resolution membrane protein X-ray and cryo-EM structures for hit finding, characterization and optimization.


Posted on August 17th, 2019

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. In October 2013 Astex became a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan. Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. For more information about Astex Pharmaceuticals, please visit


Posted on March 14th, 2019

CryoSPARC powers high-throughput cryo-EM in drug discovery by combining proprietary computer vision and machine learning algorithms with robust workflows to enable recovery of the highest quality structures, especially for valuable targets like membrane proteins.

With this investment, leadXpro complements its unique expertise of construct design, membrane protein expression and purification expert knowledge, grid freezing and cryo-EM measurement* with professional data analysis for high resolution cryo-electron microscopy. Structural details inform about the interaction of the drug target protein with small molecule or biotherapeutic ligands to facilitate the discovery, optimization and characterization of potential medicines.

*in collaboration with C-CINA of the University of Basel


Posted on February 25th, 2019

In the research project, Sanofi and leadXpro will combine their expertise in structure based drug discovery for a challenging drug target. In particular, leadXpro will contribute protein sample generation and enable structure determination by high resolution cryo-electron microscopy to inform about the interaction with small molecule ligands aiming to facilitate the discovery and optimization of novel lead molecules.

University of Zürich

Posted on February 25th, 2019

Under this research and development collaboration, leadXpro provides purified membrane protein and UZH applies their sybody platform, which is unique in generating synthetic single-domain antibodies, termed sybodies, against challenging membrane proteins. leadxpro has the option to acquire any resulting commercial applications of the developed products. The collaboration is supported by the grant 25864.1 PFLS-LS from the Swiss Innovation Agency Innosuisse.


Posted on February 25th, 2019

The collaboration brings together leadXpro’s strong expertise in structure-based drug discovery on G-protein coupled receptors with InterAx’ validated cell-based kinetic signaling assays for compound characterization. The partners aim to identify lead compounds targeting certain G-protein coupled receptors that are involved in cancer. Their complex biology so far has hampered previous lead discovery efforts.


Posted on February 25th, 2019

Creoptix provides leadXpro with the Creoptix WAVEdelta system, its latest technology for real-time label-free molecular interaction analysis. The WAVEdelta combines highest sensitivity and the broadest sample compatibility, which is especially important when working with membrane proteins. leadXpro will combine the WAVE technology with its expertise in assay development, high throughput screening, membrane protein generation, structure determination and application of further biophysical methods. Accurate characterization of the speed at which drug molecule bind to and dissociate from their therapeutic target helps fine-tuning the design of new drug molecules. LeadXpro researchers will investigate the interaction of small molecules and biotherapeutics with ion channels, transporters and G-protein receptors to facilitate the discovery and optimization of novel drug lead molecules.


Posted on December 8th, 2017

About BASF’s Crop Protection division

With a rapidly growing population, the world is increasingly dependent on our ability to develop and maintain sustainable agriculture and healthy environments. BASF’s Crop Protection division works with farmers, agricultural professionals, pest management experts and others to help make this possible. With their cooperation, BASF is able to sustain an active R&D pipeline, an innovative portfolio of products and services, and teams of experts in the lab and in the field to support customers in making their businesses succeed. In 2016, BASF’s Crop Protection division generated sales of €5.6 billion. For more information, please visit us at or on any of our social media channels.


Posted on November 1st, 2017

About Axxam SpA

Axxam is an innovative Partner Research Organization (iPRO). It is a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. AXXAM has consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures. For more information, please visit



Posted on April 3rd, 2017

Bayer Healthcare’s research focuses on new therapies for the treatment of diseases where there is a high level of medical need, such as cancer and cardiovascular diseases.

Boehringer Ingelheim

Posted on April 3rd, 2017

Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. (from Boehringer’s global website)

On november 6, 2016 Boehringer Ingelheim and leadXpro AG announced their partnership to enable structure based drug discovery and the use of biophysical methods for projects with challenging membrane protein drug targets.

Sosei Heptares Therapeutics

Posted on December 22nd, 2016

Heptares’ proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Heptares’ ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva. [cited from Heptares’ website].

Heptares is a wholly owned subsidiary of Sosei Group Corporation.


Posted on July 1st, 2016

From Salipro’s webpage: Salipro® nanoparticles are formed via a defined self-assembly process.  The scaffold protein and lipids assemble around the membrane protein and reconstitute it in a nanoscale lipid environment. Using Salipro®, it is possible to work with membrane proteins as if they were soluble proteins. It is possible to incorporate various classes of membrane proteins into the Salipro® nanoparticles: Human, bacterial, viral, GPCR, channels, transporters, receptors etc.

Center for Cellular Imaging and Nano-Analytics

Posted on June 3rd, 2016

Its research focus is on membrane protein structure-function relationships of and on aggregation mechanisms involved in neurodegeneration relevant to Alzheimer’s and Parkinson’s disease.

The C-CINA research groups are led by Henning StahlbergJan Peter AbrahamsThomas Braun.

Paul Scherrer Institute

Posted on June 2nd, 2016

World renowned large research facility and home of 1,900 highly innovative national and international scientists. International membrane protein structural biology hub and home to the the Swiss Light Source SLS synchrotron X-ray instrument and the Free Electron Laser SwissFEL. (a Free Electron Laser).

leadXpro is a spin-off from the Paul Scherrer Institute. Its co-location fosters close collaborations with PSI scientists and provides direct access to the research facilities. Find out more about the Paul Scherrer Institute on the PSI website.

It is one of only two locations in the world providing the three complementary probes of synchrotron X-rays, neutrons and muons at one site. Read more about it on the PSI website. Most important for LeadXpro are the access to the Swiss Light Source SLS and the Free Electron Laser SwissFEL.


Posted on June 1st, 2016

Located in close proximity to the Paul Scherrer Institute (PSI) and its unique complex of large research facilities, Switzerland Innovation PARK INNOVAARE and the companies based there profit from the extensive collaboration opportunities with leading experts in four innovation focus areas: accelerator technology, advanced materials and processes, humans and health, and energy.

This website is using cookies. If you continue to use this site you agree to our privacy policy. Our privacy policy